Patients with statin resistance do not experience symptoms, Le noted. Instead, the problem is that statins do not lower LDL-C levels as much as they typically do. Instead of a 50% reduction, people ...
DEAR DR. ROACH: I’m a healthy 50-year-old woman. I asked my doctor to test me for Lipoprotein(a) after reading about it. My level was high, at 41 mg/dL. My doctor told me that it didn’t need to be ...
Two pharma companies developing lipid-lowering drugs, MSD and Ionis, have reported positive phase 3 data that open the way for regulatory filings in the coming months. First up, MSD, which chalked up ...
Chronic and lifestyle diseases like high cholesterol, fatty liver disease, and chronic kidney disease (CKD) have reached epidemic levels in India, largely driven by sedentary habits, poor diet, and ...
Dear Dr. Roach: I’m a healthy 50-year-old woman. I asked my doctor to test me for Lipoprotein(a) after reading about it. My level was high, at 41 mg/dL. My doctor told me that it didn’t need to be ...
Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...
Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced the presentation of compelling new findings from the REPATHA-CE study of ...
AUSTIN, Texas and TOKYO, Nov. 14, 2025 /PRNewswire/ -- According to DataM Intelligence, the Cardiovascular Biologics Market Size was valued at approximately USD 2.20 billion in 2024 and is projected ...
Not only have the Fighting Irish won eight in a row, but all eight have been comfortable, multi-score victories. With a dreadful Syracuse offense coming to town, that kind of performance should be the ...
Lauren (Hansen) Holznienkemper is a lead editor for the small business vertical at Forbes Advisor, specializing in HR, payroll and recruiting solutions for small businesses. Using research and writing ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback